AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3827416
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 10 mg administered sublingually after 120 minutes to placebo-pretreated patients
Trial: 3827416
Drug: Conventional antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antihypertensive medications and bed rest (Control)
Trial: 23159232
Drug: No darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No darbepoetin alfa doses
Trial: 23159232
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of darbepoetin alfa
Trial: 23159232
Drug: 2-4 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-4 doses of darbepoetin alfa
Trial: 23159232
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or more doses of darbepoetin alfa
Trial: 17904834
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with salmeterol and fluticasone
Trial: 16614542
Drug: Topiramate 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 25, 50, and 100 mg daily
Trial: 12657970
Drug: Corticosteroid infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid infusion for 48 hours after significant head injury
Trial: 8436235
Drug: Sterile vaseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile vaseline ointment
Trial: 30293467
Drug: Dezocine-based local
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dezocine-based local anesthesia (preoperative intramuscular injection of dezocine)
Trial: 30293467
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dezocine injection)
Trial: 24884578
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (vancomycin or anti-staphylococcal penicillin)
Trial: 27629750
Drug: Berberine treatment
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine treatment
Trial: 28176235
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg SC sumatriptan (DFN-11)
Trial: 16151760
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg SC sumatriptan
Trial: 23423871
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser (PDL) plus topical tazarotene 0.1% cream
Trial: 15057741
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a 180 microg/wk plus ribavirin 1000-1200 mg/day
Trial: 15057741
Drug: Ribavirin dose
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin dose reduction from > or =80% to < or =60% of the starting dose during the first 20 weeks of treatment
Trial: 15057741
Drug: Peginterferon or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon or ribavirin dose reduction after week 20
Trial: 9663362
Drug: Venlafaxine 37.5
RxNorm normalized name: venlafaxine 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5 mg twice daily (increased to 75 mg if needed)
Trial: 9663362
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg once daily (increased to 40 mg if needed)
Trial: 30912213
Drug: 50:50 mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50:50 mixed analog insulin (Humalog® Mix50/50™)
Trial: 30912213
Drug: 30:70 mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30:70 mixed human insulin
Trial: 26165264
Drug: Implant removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant removal
Trial: 26165264
Drug: No implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No implant removal (Control)
Trial: 21607821
Drug: Extralight titanized
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extralight titanized polypropylene mesh (ELW group) TiMesh(®) 16 g/m(2) without any fixation
Trial: 21607821
Drug: Standard heavyweight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heavyweight polypropylene mesh (HW group) Prolene 90 g/m(2) fixed with two absorbable sutures
Trial: 16438762
Drug: Esomeprazole 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 3 x 40 mg
Trial: 12559678
Drug: hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (HCTZ) (25 mg)
Trial: 11436909
Drug: Narcotic analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic analgesia administered in the emergency department (ED)
Trial: 7530026
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies to HIVLAI
Trial: 20825901
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (including furosemide, oxygen, and high-dose boluses of isosorbide dinitrate)
Trial: 19515413
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg once a day
Trial: 19515413
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 microg twice a day
Trial: 15612859
Drug: High-dose nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nicotine (35 mg) patch
Trial: 11282204
Drug: Meningococcal serogroup
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal serogroup C conjugate vaccine (MenC)
Trial: 3081923
Drug: Yohimbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (30 mg)
Trial: 3081923
Drug: Alprazolam (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1.5 mg) and Yohimbine (30 mg) together
Trial: 23090523
Drug: Hydrocodone-acetaminophen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-acetaminophen (10 mg hydrocodone and 650 mg acetaminophen)
Trial: 23090523
Drug: Hydrocodone-acetaminophen
RxNorm normalized name: Dolorex Forte (hydrocodone / acetaminophen) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-acetaminophen
Trial: 16124155
Drug: Nerve stimulator-guided
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve stimulator-guided and double-injection (ND) group
Trial: 16124155
Drug: Ultrasound-guided and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided and double-injection (UD) group
Trial: 16124155
Drug: Ultrasound-guided and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided and single-injection (US) group
Trial: 8619007
Drug: DN-2327 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DN-2327 (3 mg)
Trial: 23672055
Drug: Alprazolam (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.8 mg)
Trial: 8619007
Drug: DN-2327 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DN-2327 (2 mg)
Trial: 2057271
Drug: Non-hypnotic distraction/relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-hypnotic distraction/relaxation
Trial: 29402064
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous alteplase (0.6 mg/kg)
Trial: 29402064
Drug: Standard-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose intravenous alteplase (0.9 mg/kg)
Trial: 23394510
Drug: Routine ED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine ED treatment including oral prednisone at 60 mg and inhalation of nebulized albuterol and ipratropium
Trial: 24200100
Drug: Conventional Treatment
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Treatment (CT)
Trial: 10480222
Drug: Oral protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral protein supplement (7.8 g/d)
Trial: 9124982
Drug: Cefpirome treatment
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome treatment for wound infections
Trial: 9124982
Drug: Cefpirome treatment
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome treatment for burn infections
Trial: 1832209
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate (20 mg)
Trial: 11842065
Drug: 3.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 g/kg of [(13)C]glucose (approximately 2 g/min)
Trial: 3302110
Drug: Gabapentin 900
RxNorm normalized name: gabapentin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg/day
Trial: 9818846
Drug: Gabapentin 1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 1,800 mg/day
Trial: 7981446
Drug: OC users
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC users with low estrogen receptor content
Trial: 7981446
Drug: OC users
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC users with low progesterone receptor content
Trial: 31426673
Drug: Standard-of-care endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care endocrine monotherapy treatment (fulvestrant or an aromatase inhibitor, per investigator's choice)
Trial: 19764666
Drug: Single layer
RxNorm normalized name: Bayer Aspirin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single layer closure (closure of skin and subcutaneous tissues together)
Trial: 19764666
Drug: Two layer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two layer closure (closure of skin and subcutaneous tissues separately)
Trial: 9532327
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g every 8 hours for 3-14 days, average 9 days)
Trial: 9532327
Drug: Ceftazidime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (1 g every 8 hours) and Amikacin (0.5 g every 12 hours for 2-14 days, average 9 days)
Trial: 31707500
Drug: Daily symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily symptom screening using the SPARK platform
Trial: 28954640
Drug: β2‐1 fructan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β2‐1 fructan (3×5 g/d)
Trial: 28954640
Drug: Maltodextrin (3×5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (3×5 g/d)
Trial: 20945252
Drug: Implementation intention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Implementation intention intervention to increase fruit and vegetable intake by two extra portions daily over 7 days
Trial: 11386392
Drug: Therapy plus
RxNorm normalized name: Lubriderm Advanced Therapy Plus Ceramide Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy plus imagery (10-minute guided imagery sessions after each therapy session, plus home practice twice weekly)
Trial: 11386392
Drug: Therapy only
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy only (control group)
Trial: 10359885
Drug: R-salbutamol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-salbutamol 1.25 mg
Trial: 10359885
Drug: Racemic salbutamol
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic salbutamol 2.5 mg
Trial: 10359885
Drug: S-salbutamol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-salbutamol 1.25 mg
Trial: 27302721
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST) provided by a bilingual social worker
Trial: 24843974
Drug: Blank group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank group (no treatment before surgery)
Trial: 19014834
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg + Simvastatin 40 mg
Trial: 19014834
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg + Simvastatin 20 mg
Trial: 19014834
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg + Simvastatin 40 mg
Trial: 19014834
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg + Simvastatin 20 mg
Trial: 19014834
Drug: Valsartan 160/320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160/320 mg + Simvastatin 20 mg
Trial: 19014834
Drug: Valsartan 160/320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160/320 mg + Simvastatin 40 mg
Trial: 16898379
Drug: Alternative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative therapy failure criteria
Trial: 16898379
Drug: WHO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO therapy failure criteria
Trial: 11185634
Drug: Oral telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral telmisartan 20 mg
Trial: 11185634
Drug: Oral telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral telmisartan 120 mg
Trial: 11185634
Drug: Intravenous telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous telmisartan 120 mg
Trial: 11185634
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and i.v. telmisartan
Trial: 11185634
Drug: Oral telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral telmisartan
Trial: 8858631
Drug: Subconjunctival mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival mitomycin-C (MMC) administration (0.27 mg/ml for 5 minutes)
Trial: 8858631
Drug: Intrascleral mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrascleral mitomycin-C (MMC) administration (0.27 mg/ml for 5 minutes)
Trial: 1298601
Drug: Selenium yeast
RxNorm normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium yeast 200 g Se1Tab/day
Trial: 29608685
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (control arm)
Trial: 26869191
Drug: Omarigliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omarigliptin (50 mg, once weekly for 4 weeks)
Trial: 15809885
Drug: Deferiprone 75
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone 75 mg/kg daily for 12 months
Trial: 12027845
Drug: ondansetron 16
RxNorm normalized name: ondansetron 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 16 mg
Trial: 329741
Drug: Cyclophosphamide as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide as a single agent
Trial: 329741
Drug: Actinomycin D‐‐vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actinomycin D‐‐vincristine combination
Trial: 329741
Drug: Cyclophosphamide‐‐methotrexate‐‐vincristine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide‐‐methotrexate‐‐vincristine combination
Trial: 16566622
Drug: Imipramine (209
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (209 mg/day, SD: 91.7, range: 75-325 mg/day)
Trial: 9777685
Drug: Immunochemotherapy as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemotherapy as an adjuvant treatment after curative resection of gastric cancer
Trial: 3344781
Drug: Anterior chamber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior chamber lenses with posterior capsule left intact
Trial: 3344781
Drug: Anterior chamber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior chamber lenses with ruptured posterior capsule
Trial: 28197749
Drug: Lifestyle-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle-based training (two weekly group sessions lasting 60-90 minutes)
Trial: 26164666
Drug: 2-L PEG
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L PEG plus bisacodyl
Trial: 21071497
Drug: Deferasirox therapy
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox therapy
Trial: 23590671
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no deferasirox therapy)
Trial: 10868020
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of Triamcinolonhexacetonide
Trial: 27281799
Drug: Immediate-release arginine
RxNorm normalized name: arginine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release arginine (IR-Arg) 1.5 g, 3 times/day
Trial: 27281799
Drug: Sustained-release arginine
RxNorm normalized name: arginine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release arginine (SR-Arg) 1.5 g, 3 times/day
Trial: 27281799
Drug: Sustained-release arginine
RxNorm normalized name: arginine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release arginine (SR-Arg) in HTW subjects
Trial: 27281799
Drug: Immediate-release arginine
RxNorm normalized name: arginine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release arginine (IR-Arg) in HTW subjects
Trial: 27281799
Drug: Sustained-release arginine
RxNorm normalized name: arginine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release arginine (SR-Arg) in CON subjects
Trial: 12438559
Drug: ISIS 104838
RxNorm normalized name: ISIS 104838
DrugBank: ISIS 104838 (DB16201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 104838 (20‐mer phosphorothioate antisense oligonucleotide) administered intravenously (i.v.) at doses of 0.1-6 mg/kg
Trial: 12438559
Drug: ISIS 104838
RxNorm normalized name: ISIS 104838
DrugBank: ISIS 104838 (DB16201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 104838 (20‐mer phosphorothioate antisense oligonucleotide) administered intravenously (i.v.)
Trial: 12438559
Drug: ISIS 104838
RxNorm normalized name: ISIS 104838
DrugBank: ISIS 104838 (DB16201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 104838 (20‐mer phosphorothioate antisense oligonucleotide) administered subcutaneously (s.c.)
Trial: 7562881
Drug: Slow-release nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release nifedipine 20 mg twice daily for 4 weeks
Trial: 1710802
Drug: Carbimazole (antithyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole (antithyroid drug) for 18 months
Trial: 1710802
Drug: Antithyroid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drug for 6 months
Trial: 1710802
Drug: Antithyroid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drug for 18 months
Trial: 1710802
Drug: Post-treatment clinical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment clinical course
Trial: 6274563
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg/kg) after 8 weeks
Trial: 21980168
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg MDMA
Trial: 21980168
Drug: 1.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg/kg MDMA
Trial: 21983032
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg MDMA and 1.6 mg/kg MDMA
Trial: 11573514
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser irradiation (G 1, 2 Hz and 136‐184 mJ/pulse)
Trial: 11573514
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser irradiation (G 2, 2 Hz and 170‐230 mJ/pulse)
Trial: 11573514
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy laser irradiation (G 2)
Trial: 1539791
Drug: Timolol ophthalmic
RxNorm normalized name: timolol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol ophthalmic solution 0.25%
Trial: 31356475
Drug: 4% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% albumin in lactated Ringer's solution